Skip to Content

New Drug Approvals Archive - December 2008

See also: New Indications and Dosage Forms for December 2008

December 2008

Lusedra (fospropofol disodium) Injection

Date of Approval: December 12, 2008
Company: Eisai Corporation of North America
Treatment for: Sedation

Marketing Status: Discontinued

Lusedra (fospropofol disodium) is an intravenous sedative-hypnotic agent for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.

Trilipix (fenofibric acid) Delayed-Release Capsules

Date of Approval: December 15, 2008
Company: Abbott
Treatment for: Hypertriglyceridemia, Hyperlipidemia

Trilipix (fenofibric acid) is a peroxisome proliferator receptor alpha (PPARα) activator indicated for use along with diet to help lower triglycerides and LDL cholesterol, and to raise HDL cholesterol in patients with lipid problems. Trilipix is the first and only fibrate to be approved for use in combination with a statin.

Mozobil (plerixafor)

Date of Approval: December 15, 2008
Company: Genzyme Corporation
Treatment for: Bone Marrow Transplantation

Mozobil (plerixafor) is a small molecule CXCR4 chemokine receptor antagonist used in combination with granulocyte-colony stimulating factor to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma.

Oforta (fludarabine phosphate) Tablets

Date of Approval: December 18, 2008
Company: sanofi-aventis U.S.
Treatment for: Chronic Lymphocytic Leukemia

Marketing Status: Discontinued

Oforta (fludarabine phosphate) is an oral nucleoside analogue approved as a single agent for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL).

Zolpimist (zolpidem tartrate) Oral Spray

Date of Approval: December 19, 2008
Company: NovaDel Pharma, Inc.
Treatment for: Insomnia

Zolpimist is an oral spray formulation of zolpidem, the drug contained in Ambien. Zolpimist is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.

Ablavar (gadofosveset trisodium) - formerly Vasovist

Date of Approval: December 22, 2008
Company: EPIX Pharmaceuticals, Inc.
Treatment for: Diagnostic

Marketing Status: Discontinued

Ablavar (gadofosveset trisodium) is a blood pool magnetic resonance angiography (MRA) agent used to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.

Firmagon (degarelix) for Injection

Date of Approval: December 24, 2008
Company: Ferring Pharmaceuticals, USA
Treatment for: Prostate Cancer

Firmagon (degarelix) is an injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for patients with advanced prostate cancer.

Latisse (bimatoprost) Ophthalmic Solution

Date of Approval: December 24, 2008
Company: Allergan, Inc.
Treatment for: Hypotrichosis of Eyelashes

Latisse (bimatoprost ophthalmic) is a prostamide indicated for the treatment of hypotrichosis (or reduced amount of hair) of the eyelashes. Growth of the eyelashes is a well documented side effect of bimatoprost which is currently approved as Lumigan for the treatment of glaucoma.

Ryzolt (tramadol) Extended Release Tablets

Date of Approval: December 30, 2008
Company: Labopharm Inc.
Treatment for: Pain

Marketing Status: Discontinued

Ryzolt (tramadol extended release) is a once-daily analgesic indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.

Nexterone (amiodarone HCl) Injection

Date of Approval: December 24, 2008
Company: Prism Pharmaceuticals
Treatment for: Ventricular Fibrillation, Ventricular Tachycardia

Nexterone (amiodarone HCl) Injection is a cosolvent free formulation of the antiarrhythmic agent Amiodarone IV, originally marketed in the US by Wyeth as Cordarone Intravenous. Nexterone is indicated for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.

Epiduo (adapalene and benzoyl peroxide) Gel

Date of Approval: December 8, 2008
Company: Galderma Laboratories, L.P.
Treatment for: Acne

Epiduo (adapalene and benzoyl peroxide) Gel is a once-daily, topical retinoid and antimicrobial combination for the treatment of acne.

New Drug Approvals Archive

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.